{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:24:33Z","timestamp":1788384273660,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer whose incidence is growing parallel to the lengthening of the average lifespan. Cemiplimab, an antiPD-1 monoclonal antibody, is the first approved immunotherapy for patients with locally advanced CSCC (laCSCC) or metastatic CSCC (mCSCC) thanks to phase I and II studies showing high antitumor activity and good tolerability. Nevertheless, at present, very few data are available regarding cemiplimab in real-life experience and in frail, elderly, and immunosuppressed patients as well as regarding biomarkers able to predict response so as to guide therapeutic choices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>We built a retroprospective cohort study including 30 non-selected patients with laCSCC (25) and mCSCC (five) treated with cemiplimab from August 2019 to November 2020. Clinical outcomes, toxicity profile, and correlations with disease, patients, and peripheral blood parameters are explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 81 years (range, 36\u201395), with 24 males and five patients having an immunosuppressive condition, while the frailty prevalence was 83% based on index derived from age, Eastern Cooperative Oncology Group performance status, and Charlson Comorbidity Index. We reported 23 responses (76.7%) with nine complete responses (30%). A statistically significant higher response rate was observed in head and neck primary tumors and in patients with hemoglobin level &amp;gt;12 g\/dl. No difference was observed with respect to frailty, median age, sex, and body mass index. The baseline low neuthophil\/lymphocyte ratio and low platelet\/lymphocyte ratio resulted to be also correlated with a better response. Moreover, lymphocyte, neutrophil, and monocyte behaviors had an opposite trend in responders and non-responders. An overall response was reported in four of five immunosuppressed patients. Seventeen patients (57.6%) have an ongoing response and are still alive. Six responders had interrupted treatment (two for toxicity and four for personal choice) but maintained their response. The treatment was well tolerated by the majority of patients. The most common adverse events were fatigue in seven patients (23.3%) and skin toxicity in 10 patients (33.3%), including pruritus in six patients, rash in three patients, and bullous erythema in one patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In our real-life experience, cemiplimab showed a high antitumor activity with acceptable safety profile similar to those in trials with selected patients. Moreover, its antitumor activity resulted to be not impaired in very elderly patients and in those with immunocompromised status.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.686308","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T05:30:06Z","timestamp":1636349406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy"],"prefix":"10.3389","volume":"11","author":[{"given":"Sabino","family":"Strippoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Fanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Quaresmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Armenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Figliuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Filotico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Traversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta Sara","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustachio","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ferraiuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Macina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Monica","family":"Sciacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"De Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Massafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/jid.2013.304","article-title":"Non-Melanoma Skin Cancer Incidence and Impact of Skin Cancer Screening on Incidence","volume":"134","author":"Eisemann","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous Squamous Cell Carcinoma: Estimated Incidence of Disease, Nodal Metastasis, and Deaths From Disease in the United States, 2012","volume":"68","author":"Karia","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0437-2_7","article-title":"Epidemiology of Skin Cancer","volume":"810","author":"Leiter","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs529","article-title":"HIV Infection Status, Immunodeficiency, and the Incidence of non-Melanoma Skincancer","volume":"105","author":"Silverberg","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12208","article-title":"Lymphoma-Associated Skin Cancer: Incidence, Natural History, and Clinical Management","volume":"53","author":"Brewer","year":"2014","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European Interdisciplinary Guideline on Invasive Squamous Cell Carcinoma of the Skin: Part 2","volume":"128","author":"Stratigos","year":"2020","journal-title":"Treat Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature","volume":"39","author":"Jarkowski","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2014.12.002","article-title":"Predictors of Chemotherapy Dose Reduction at First Cycle in Patients Age 65 Years and Older With Solid Tumors","volume":"6","author":"Gajra","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II Study of Cetuximab as First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.03.004","article-title":"Chromosome 3q Arm Gain Linked to Immunotherapy Response in Advanced Cutaneous Squamous Cell Carcinoma","volume":"113","author":"Kacew","year":"2019","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.103\/jid.2011.9","article-title":"Tumor-Associated Macrophages in the Cutaneous SCC Microenvironment Are Heterogeneously Activated","volume":"131","author":"Pettersen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.1609","article-title":"CD200 Upregulation in Vascular Endothelium Surrounding Cutaneous Squamous Cell Carcinoma","volume":"149","author":"Belkin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in Locally Advanced Cutaneous Squamous Cell Carcinoma: Results From an Open-Label, Phase 2, Single-Arm Trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu540","article-title":"The Prevalence and Outcomes of Frailty in Older Cancer Patients: A Systematic Review","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.715513","article-title":"Impacts of Frailty on Prognosis in Lung Cancer Patients: A Systematic Review and Meta-Analysis","volume":"22","author":"Dai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.07.029","article-title":"Programmed Cell Death Protein 1 Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Data of a Retrospective, Multicenter Study","volume":"138","author":"Salzmann","year":"2020","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03458-6","article-title":"PD-1 Inhibition Therapy for Advanced Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From the University of Southern California","volume":"147","author":"In","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01044-8","article-title":"Real-World Outcomes Treating Patients With Advanced Cutaneous Squamous Cell Carcinoma With Immune Checkpoint Inhibitors (CPI)","volume":"123","author":"Hanna","year":"2020","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1210","article-title":"Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Real Life Experience","volume":"31","author":"Hober","year":"2020","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real World Data of Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0105","article-title":"Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy","volume":"12","author":"Kartolo","year":"2020","journal-title":"Immunotherapy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107662","article-title":"Good Cops Turn Bad: The Contribution of Neutrophils to Immune-Checkpoint Inhibitor Treatment Failures in Cancer","volume":"217","author":"Zhang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of Platelets and Platelet Receptors in Cancer Metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.00165","article-title":"Improved Comorbidity Adjustment for Predicting Mortality in Medicare Populations","volume":"38","author":"Schneeweiss","year":"2003","journal-title":"Health Serv Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0","article-title":"A Simplified Frailty Scale Predicts Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated in the FIRST (MM-020) Trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S2152","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13063-020-04280-8","article-title":"Durvalumab in Frail and Elderly Patients With Stage Four Non-Small Cell Lung Cancer: Study Protocol of the Randomized Phase II DURATION Trial","volume":"21","author":"Kuon","year":"2020","journal-title":"Trials"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e000775","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 Study of Cemiplimab in Patients With Metastatic Cutaneous Squamous Cell Carcinoma: Primary Analysis of Fixed-Dosing, Long-Term Outcome of Weight-Based Dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz451.006","article-title":"Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti\u2013PD-1, in Patients (PTS) With Advanced Cutaneous Squamous Cell Carcinoma (CSCC)","volume":"30","author":"Rischin","year":"2019","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-Analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052628","article-title":"Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.12.012","article-title":"Anti-PD1 Antibodies in Patients Aged \u2265 75 Years With Metastatic Melanoma: A Retrospective Multicentre Study","volume":"11","author":"Ridolfi","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.625872","article-title":"The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease","volume":"22","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity With Ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/cncr.10523","article-title":"Anemia as an Independent Prognostic Factor for Survival in Patients With Cancer","volume":"94","author":"Watine","year":"2002","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_1066_19","article-title":"Hemoglobin, Albumin, Lymphocyte, and Platelet Score and Neutrophil-to-Lymphocyte Ratio Are Novel Significant Prognostic Factors for Patients With Small-Cell Lung Cancer Undergoing Chemotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0205-5","article-title":"Late-Stage Tumors Induce Anemia and Immunosuppressive Extramedullary Erythroid Progenitor Cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040870","article-title":"Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development","volume":"13","author":"Grzywa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920970049","article-title":"Pretreatment Hemoglobin Level as a Predictor to Evaluate the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.06.026","article-title":"Concurrent Radiation Therapy With Programmed Cell Death Protein 1 Inhibition Leads to a Complete Response in Advanced Cutaneous Squamous Cell Carcinoma","volume":"5","author":"Vaidya","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3671","article-title":"Pembrolizumab and Concurrent Hypo-Fractionated Radiotherapy for Advanced Non-Resectable Cutaneous Squamous Cell Carcinoma","volume":"29","author":"Lavaud","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918768240","article-title":"Radiotherapy and Checkpoint Inhibitors: A Winning New Combination","volume":"10","author":"Ko","year":"2018","journal-title":"Ther Adv Med Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.686308\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T05:30:08Z","timestamp":1636349408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.686308\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":48,"alternative-id":["10.3389\/fonc.2021.686308"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.686308","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"article-number":"686308"}}